Scynexis, Inc.
19
1
1
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
10.5%
2 terminated/withdrawn out of 19 trials
88.9%
+2.4% vs industry average
37%
7 trials in Phase 3/4
69%
11 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Role: lead
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Role: lead
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Role: lead
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Role: lead
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Role: lead
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Role: lead
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Role: lead
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Role: lead
ADME Study of [14^C]-Ibrexafungerp in Healthy Male Subjects
Role: lead
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Role: lead
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
Role: lead
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
Role: lead
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Role: lead
Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects
Role: lead
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
Role: lead
ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects
Role: lead
Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Role: lead
Study of SCY-635, Pegasys and Copegus in Hepatitis C
Role: lead
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients
Role: lead
All 19 trials loaded